Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 21 | 2019 | 1175 | 1.440 |
Why?
|
| Weight Loss | 19 | 2019 | 480 | 1.410 |
Why?
|
| Resistance Training | 9 | 2021 | 82 | 1.110 |
Why?
|
| Osteoarthritis, Knee | 8 | 2021 | 90 | 1.070 |
Why?
|
| Exercise | 14 | 2019 | 672 | 1.060 |
Why?
|
| Caloric Restriction | 9 | 2019 | 106 | 1.000 |
Why?
|
| Exercise Therapy | 7 | 2019 | 270 | 0.820 |
Why?
|
| Diet, Reducing | 6 | 2019 | 106 | 0.690 |
Why?
|
| Overweight | 9 | 2019 | 280 | 0.680 |
Why?
|
| Body Composition | 12 | 2019 | 397 | 0.650 |
Why?
|
| Aged | 46 | 2021 | 10301 | 0.560 |
Why?
|
| Anxiety Disorders | 4 | 2017 | 77 | 0.500 |
Why?
|
| Exercise Tolerance | 4 | 2019 | 125 | 0.430 |
Why?
|
| Telephone | 4 | 2017 | 59 | 0.420 |
Why?
|
| Female | 46 | 2021 | 19959 | 0.410 |
Why?
|
| Aging | 6 | 2017 | 946 | 0.380 |
Why?
|
| Oxygen Consumption | 6 | 2019 | 154 | 0.360 |
Why?
|
| Muscle Strength | 5 | 2015 | 161 | 0.350 |
Why?
|
| Male | 37 | 2021 | 19165 | 0.350 |
Why?
|
| Humans | 50 | 2021 | 32005 | 0.330 |
Why?
|
| Body Mass Index | 13 | 2021 | 923 | 0.330 |
Why?
|
| Hospitalization | 4 | 2015 | 470 | 0.320 |
Why?
|
| Cardiovascular Diseases | 4 | 2020 | 1128 | 0.320 |
Why?
|
| Pneumonia | 3 | 2015 | 68 | 0.300 |
Why?
|
| Adipose Tissue | 4 | 2014 | 349 | 0.290 |
Why?
|
| Knee Joint | 3 | 2021 | 142 | 0.290 |
Why?
|
| Heart Failure | 4 | 2016 | 639 | 0.280 |
Why?
|
| Middle Aged | 25 | 2021 | 11817 | 0.280 |
Why?
|
| Bone Density | 2 | 2019 | 205 | 0.280 |
Why?
|
| Weight Gain | 3 | 2012 | 117 | 0.270 |
Why?
|
| Muscle, Skeletal | 4 | 2015 | 519 | 0.260 |
Why?
|
| Mitochondria, Muscle | 2 | 2016 | 18 | 0.260 |
Why?
|
| Adiponectin | 3 | 2015 | 106 | 0.250 |
Why?
|
| Exercise Test | 4 | 2019 | 227 | 0.240 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 2265 | 0.240 |
Why?
|
| Postmenopause | 5 | 2012 | 430 | 0.220 |
Why?
|
| Blood Glucose | 5 | 2019 | 494 | 0.220 |
Why?
|
| Quadriceps Muscle | 2 | 2016 | 34 | 0.210 |
Why?
|
| Accidental Falls | 2 | 2018 | 222 | 0.210 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 3990 | 0.210 |
Why?
|
| Stroke Volume | 2 | 2016 | 348 | 0.200 |
Why?
|
| Rural Population | 4 | 2017 | 274 | 0.200 |
Why?
|
| Thiazolidinediones | 2 | 2013 | 47 | 0.200 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 181 | 0.180 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2020 | 8 | 0.180 |
Why?
|
| Quality of Life | 5 | 2019 | 946 | 0.180 |
Why?
|
| Treatment Outcome | 9 | 2019 | 3306 | 0.170 |
Why?
|
| Interleukin-6 | 4 | 2014 | 247 | 0.170 |
Why?
|
| Hypertension | 3 | 2018 | 959 | 0.160 |
Why?
|
| Gait | 1 | 2019 | 142 | 0.160 |
Why?
|
| Dietary Proteins | 1 | 2019 | 55 | 0.160 |
Why?
|
| Cytokines | 2 | 2014 | 256 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2019 | 94 | 0.160 |
Why?
|
| Syncope | 1 | 2018 | 26 | 0.150 |
Why?
|
| Prediabetic State | 1 | 2018 | 65 | 0.150 |
Why?
|
| Subcutaneous Fat | 2 | 2015 | 47 | 0.150 |
Why?
|
| Hypotension | 1 | 2018 | 47 | 0.150 |
Why?
|
| Single-Blind Method | 5 | 2021 | 203 | 0.150 |
Why?
|
| Psychotherapy, Group | 1 | 2017 | 17 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2020 | 1426 | 0.140 |
Why?
|
| Risk Factors | 9 | 2018 | 3876 | 0.140 |
Why?
|
| Pain Measurement | 5 | 2021 | 350 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 9 | 0.140 |
Why?
|
| Absorptiometry, Photon | 5 | 2019 | 143 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 54 | 0.130 |
Why?
|
| Leptin | 2 | 2014 | 71 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 66 | 0.130 |
Why?
|
| Mental Health Services | 1 | 2015 | 31 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 352 | 0.120 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2015 | 109 | 0.120 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 93 | 0.120 |
Why?
|
| Forecasting | 1 | 2015 | 143 | 0.120 |
Why?
|
| Inpatients | 1 | 2015 | 85 | 0.120 |
Why?
|
| Time Factors | 5 | 2020 | 2149 | 0.120 |
Why?
|
| Obesity, Abdominal | 1 | 2014 | 24 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 475 | 0.120 |
Why?
|
| Lipids | 1 | 2015 | 232 | 0.120 |
Why?
|
| Telemedicine | 1 | 2015 | 102 | 0.120 |
Why?
|
| Health Status | 1 | 2016 | 399 | 0.110 |
Why?
|
| Models, Educational | 1 | 2013 | 20 | 0.110 |
Why?
|
| Capillaries | 2 | 2014 | 24 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 172 | 0.110 |
Why?
|
| Paralysis | 1 | 2012 | 13 | 0.110 |
Why?
|
| Abdominal Fat | 2 | 2011 | 50 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 86 | 0.100 |
Why?
|
| Geriatrics | 1 | 2013 | 85 | 0.100 |
Why?
|
| Median Nerve | 1 | 2012 | 51 | 0.100 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2012 | 62 | 0.100 |
Why?
|
| Geriatric Assessment | 4 | 2016 | 390 | 0.100 |
Why?
|
| Adipokines | 1 | 2010 | 16 | 0.090 |
Why?
|
| Muscle Weakness | 1 | 2010 | 37 | 0.090 |
Why?
|
| Pain | 3 | 2021 | 288 | 0.090 |
Why?
|
| Age Factors | 3 | 2020 | 1188 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 495 | 0.080 |
Why?
|
| Depression | 3 | 2017 | 444 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2020 | 2282 | 0.080 |
Why?
|
| Glucose Tolerance Test | 3 | 2018 | 126 | 0.070 |
Why?
|
| Comorbidity | 3 | 2018 | 566 | 0.070 |
Why?
|
| Incidence | 3 | 2020 | 1199 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2010 | 385 | 0.070 |
Why?
|
| Body Fat Distribution | 2 | 2017 | 34 | 0.070 |
Why?
|
| Energy Intake | 2 | 2019 | 128 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 510 | 0.060 |
Why?
|
| Hand Strength | 1 | 2005 | 101 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 135 | 0.060 |
Why?
|
| Seafood | 1 | 2004 | 11 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 1497 | 0.060 |
Why?
|
| Social Support | 2 | 2016 | 181 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 753 | 0.060 |
Why?
|
| Mortality | 1 | 2005 | 125 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3509 | 0.060 |
Why?
|
| Disability Evaluation | 2 | 2019 | 240 | 0.060 |
Why?
|
| Anxiety | 2 | 2015 | 191 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 560 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2015 | 1817 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2016 | 898 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2017 | 199 | 0.050 |
Why?
|
| Weight-Bearing | 2 | 2013 | 40 | 0.050 |
Why?
|
| Aorta | 1 | 2002 | 126 | 0.050 |
Why?
|
| Blood Pressure | 2 | 2018 | 845 | 0.050 |
Why?
|
| Compressive Strength | 1 | 2021 | 23 | 0.050 |
Why?
|
| North Carolina | 2 | 2017 | 1514 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2004 | 322 | 0.040 |
Why?
|
| Cognition | 2 | 2019 | 555 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 100 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 881 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 57 | 0.040 |
Why?
|
| Hip | 1 | 2019 | 15 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 85 | 0.040 |
Why?
|
| Arthralgia | 1 | 2019 | 33 | 0.040 |
Why?
|
| Cholesterol, HDL | 2 | 2012 | 177 | 0.040 |
Why?
|
| Femur | 1 | 2019 | 74 | 0.040 |
Why?
|
| Self Efficacy | 1 | 2019 | 78 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 226 | 0.040 |
Why?
|
| Fasting | 1 | 2018 | 95 | 0.040 |
Why?
|
| Triglycerides | 2 | 2012 | 230 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2019 | 101 | 0.040 |
Why?
|
| Diet | 2 | 2015 | 391 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 371 | 0.040 |
Why?
|
| Femur Neck | 1 | 2017 | 21 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 545 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 30 | 0.040 |
Why?
|
| Insulin | 2 | 2012 | 367 | 0.040 |
Why?
|
| Postural Balance | 1 | 2019 | 182 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2010 | 210 | 0.030 |
Why?
|
| Citrate (si)-Synthase | 1 | 2016 | 3 | 0.030 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 125 | 0.030 |
Why?
|
| Torque | 1 | 2015 | 20 | 0.030 |
Why?
|
| United States | 2 | 2020 | 3939 | 0.030 |
Why?
|
| Muscle Fibers, Slow-Twitch | 1 | 2015 | 20 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2015 | 19 | 0.030 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2015 | 30 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 97 | 0.030 |
Why?
|
| Sleep | 1 | 2016 | 92 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 1531 | 0.030 |
Why?
|
| Insulin Resistance | 2 | 2012 | 462 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2015 | 114 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 138 | 0.030 |
Why?
|
| Life Style | 1 | 2017 | 408 | 0.030 |
Why?
|
| Microcirculation | 1 | 2014 | 65 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 268 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2015 | 126 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2015 | 165 | 0.030 |
Why?
|
| Adult | 2 | 2018 | 9345 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 594 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2013 | 123 | 0.030 |
Why?
|
| Wrist | 1 | 2012 | 48 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 463 | 0.030 |
Why?
|
| Neural Conduction | 1 | 2012 | 91 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 173 | 0.020 |
Why?
|
| Body Fluid Compartments | 1 | 2011 | 5 | 0.020 |
Why?
|
| Curriculum | 1 | 2013 | 213 | 0.020 |
Why?
|
| Choristoma | 1 | 2011 | 17 | 0.020 |
Why?
|
| Thigh | 1 | 2011 | 42 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2011 | 46 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2010 | 24 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 333 | 0.020 |
Why?
|
| Sarcopenia | 1 | 2011 | 64 | 0.020 |
Why?
|
| Physical Examination | 1 | 2010 | 92 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 530 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 297 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2008 | 9 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 93 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 104 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2015 | 766 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2009 | 219 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 313 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 762 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 876 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 918 | 0.020 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2005 | 5 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2005 | 108 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2004 | 44 | 0.020 |
Why?
|
| Tuna | 1 | 2004 | 1 | 0.020 |
Why?
|
| Fishes | 1 | 2004 | 8 | 0.020 |
Why?
|
| Massachusetts | 1 | 2004 | 27 | 0.020 |
Why?
|
| Abdomen | 1 | 2004 | 43 | 0.020 |
Why?
|
| Fish Oils | 1 | 2004 | 36 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2004 | 48 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 177 | 0.010 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2004 | 57 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 105 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2004 | 110 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 684 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 321 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 1328 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 2002 | 26 | 0.010 |
Why?
|
| Smoking | 1 | 2005 | 497 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 191 | 0.010 |
Why?
|
| Heart Rate | 1 | 2002 | 335 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 767 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 7541 | 0.010 |
Why?
|